Page 126 - 《中国药房》2023年22期

杂志，2020，40（9）：1021-1028. [16] MARKOWITZ J N，FANCHER K M. Cabozantinib：a
Chinese Thyroid Association，Chinese Collage of Sur‐ multitargeted oral tyrosine kinase inhibitor[J]. Pharmaco‐
geons，Chinese Medical Doctor Association，Chinese Re‐ therapy，2018，38（3）：357-369.
search Hospital Association Thyroid Disease Committee. [17] SALTIKI K，SIMEAKIS G，KARAPANOU O，et al. Mana-
Expert consensus on postoperative management of dif- gement of endocrine disease：medullary thyroid cancer：
ferentiated thyroid cancer（2020 edition）[J]. Chin J Pract from molecular biology and therapeutic pitfalls to future
Surg，2020，40（9）：1021-1028. targeted treatment perspectives[J]. Eur J Endocrinol，
[ 7 ] CABANILLAS M E，RYDER M，JIMENEZ C. Targeted 2022，187（3）：R53-R63.
therapy for advanced thyroid cancer：kinase inhibitors and [18] BROSE M S，NUTTING C M，JARZAB B，et al.
beyond[J]. Endocr Rev，2019，40（6）：1573-1604. Sorafenib in radioactive iodine-refractory，locally advanced
[ 8 ] EFSTATHIADOU Z A，TSENTIDIS C，BARGIOTA A，et or metastatic differentiated thyroid cancer：a randomised，
al. Benefits and limitations of TKIs in patients with medul‐ double-blind，phase 3 trial[J]. Lancet，2014，384（9940）：
lary thyroid cancer：a systematic review and meta-analysis 319-328.
[J]. Eur Hyroid J，2021，10（2）：125-139. [19] SCHLUMBERGER M，TAHARA M，WIRTH L J，et al.
[ 9 ] DUKE E S，BARONE A K，CHATTERJEE S，et al. FDA Lenvatinib versus placebo in radioiodine-refractory thy‐
approval summary：cabozantinib for differentiated thyroid roid cancer[J]. N Engl J Med，2015，372（7）：621-630.
cancer[J]. Clin Cancer Res，2022，28（19）：4173-4177. [20] KOEHLER V F，ADAM P，FRANK-RAUE K，et al. Real-
[10] HIGGINS J P T，ALTMAN D G，GØTZSCHE P C，et al. world efficacy and safety of cabozantinib and vandetanib
The Cochrane collaboration’s tool for assessing risk of in advanced medullary thyroid cancer[J]. Thyroid，2021，
bias in randomised trials[J]. BMJ，2011，343：d5928. 31（3）：459-469.
[11] BROSE M S，ROBINSON B，SHERMAN S I，et al. Cabo‐ [21] 韩俊伟，李元平，程瑶，等. 血管内皮生长因子受体酪氨
zantinib for radioiodine-refractory differentiated thyroid 酸激酶抑制剂致肿瘤患者发生严重胃肠道事件风险的网
cancer（COSMIC-311）：a randomised，double-blind， 状meta分析[J]. 药物不良反应杂志，2022，24（3）：130-138.
placebo-controlled，phase 3 trial[J]. Lancet Oncol，2021， HAN J W，LI Y P，CHENG Y，et al. Risk of severe gastro‐
22（8）：1126-1138. intestinal events in patients with cancer caused by vascu‐
[12] BROSE M S，ROBINSON B G，SHERMAN S I，et al. lar endothelial growth factor receptor tyrosine kinase
Cabozantinib for previously treated radioiodine-refractory inhibitors：a network meta-analysis[J]. Adverse Drug Re‐
differentiated thyroid cancer：updated results from the act J，2022，24（3）：130-138.
phase 3 COSMIC-311 trial[J]. Cancer，2022，128（24）： [22] KLEIN HESSELINK E N，STEENVOORDEN D，
4203-4212. KAPITEIJN E，et al. Therapy of endocrine disease：
[13] ELISEI R，SCHLUMBERGER M J，MÜLLER S P，et al. response and toxicity of small-molecule tyrosine kinase
Cabozantinib in progressive medullary thyroid cancer[J]. J inhibitors in patients with thyroid carcinoma：a systematic
Clin Oncol，2013，31（29）：3639-3646. review and meta-analysis[J]. Eur J Endocrinol，2015，172
[14] SCHLUMBERGER M，ELISEI R，MÜLLER S，et al. （5）：R215-R225.
Overall survival analysis of EXAM，a phase Ⅲ trial of [23] TSANG V H M. Management of treatment-related toxici‐
cabozantinib in patients with radiographically progressive ties in advanced medullary thyroid cancer[J]. Curr Opin
medullary thyroid carcinoma[J]. Ann Oncol，2017，28 Oncol，2019，31（3）：236-242.
（11）：2813-2819. [24] WIRTH L J，TAHARA M，ROBINSON B，et al.
[15] 中国抗癌协会甲状腺癌专业委员会，中国抗癌协会头颈 Treatment-emergent hypertension and efficacy in the
肿瘤专业委员会，中华医学会肿瘤学分会甲状腺肿瘤专 phase 3 study of （E7080） lenvatinib in differentiated can‐
业委员会，等. 晚期甲状腺癌靶向药物应用中国专家共识： cer of the thyroid（SELECT）[J]. Cancer，2018，124（11）：
2022年版[J]. 中华普通外科杂志，2022，37（12）：881-889. 2365-2372.
Thyroid Cancer Professional Committee of Chinese Anti- [25] ENOKIDA T，TAHARA M. Management of VEGFR-
Cancer Association，Head and Neck Cancer Professional targeted TKI for thyroid cancer[J]. Cancers，2021，13
Committee of Chinese Anti-cancer Association，Thyroid （21）：5536.
Cancer Professional Committee of Oncology Branch of [26] BROSE M S，SMIT J，LIN C C，et al. Timing of multiki‐
Chinese Medical Association，et al. China expert consen‐ nase inhibitor initiation in differentiated thyroid cancer[J].
sus on the application of targeted drugs for advanced thy‐ Endocr Relat Cancer，2017，24（5）：237-242.
roid cancer：2022 edition[J]. Chin J Gen Surg，2022，37 （收稿日期：2023-04-03 修回日期：2023-10-19）
（12）：881-889. （编辑：陈 宏）

· 2804 · China Pharmacy 2023 Vol. 34 No. 22 中国药房 2023年第34卷第22期